Basic/Translational Science

Lung Cancer Control and Epidemiology

Non-Smoking Related Lung Cancer
  1. Postulated mechanisms for non-smoking related lung cancer
  2. Magnitude of the problem world wide
  3. Variance with ethnicity and geography
Gender-Related Differences in Lung Cancer
  1. Differences in susceptibility and outcomes of lung cancer in men and women
  2. Postulated reasons for those differences


Lung Cancer Molecular Carcinogenesis

Copy Number Abnormalities and Gene Rearrangements in Lung Cancer: Present and Developing Technologies
  1. Most common chromosomal abnormalities in lung cancer
  2. How FISH and CGH can identify these abnormalities
  3. Functional implications of these abnormalities
Mutational Events in Lung Cancer: Present and Developing Technologies
  1. Techniques used for the discovery of lung cancer mutations
  2. Frequency of those mutations
  3. Molecular pathway implications of those mutations
Epigenetic Events, Alterations, and Remodeling in Lung Cancer: Present and Developing Technologies
  1. Functional implications and causes of methylation
  2. How to measure methylation
  3. Most common methylated species and the implications of methylation in lung cancer
Stem Cells and Lung Cancer: In Vitro and In Vivo Studies
  1. Describe the characterization of lung cancer stem cells
  2. Summarize current knowledge on stem cell signaling pathways and cell markers used to identify the lung cancer stem cells
  3. Review relevant in vitro and in vivo studies
Microenvironment and Lung Cancer
  1. Initiation of lung cancer carcinogenesis: role of the local environment/inflammation
  2. Discussion of how the microenvironment promotes sustained growth of lung cancer either through the cytokine release or direct cellular contact
MicroRNAs as Biomarkers for Lung Cancer
  1. Address importance of microRNAs in the diagnosis, prognostication and treatment response prediction
Humoral and Cellular Immune Dysregulation and Lung Cancer
  1. Basic immunologic discussion of abnormalities both cellular and humoral in lung cancer



Molecular Testing and Lung Cancer
  1. Discussion of molecular tests which have clinical relevance at this time
  2. Discuss methods for obtaining material for testing and requirements
  3. Discuss the problems and advantages of platforms used to do these molecular tests
  4. Discuss promising new molecular markers for the future
Management of the Small Biopsy in the Molecular Era


Clinical and Radiologic Presentation of Lung Cancer

Clinical Presentation
  1. Symptoms and signs of non small cell lung cancer
  2. Symptoms and signs of small cell lung cancer
  3. Describe paraneoplastic and other syndromes associated with NSCLC
  4. Clinical and molecular methods for the prognostication of lung cancer
Conventional Imaging Lung Cancer


  1. Utility of chest x-ray and computerized tomography in the diagnosis of lung cancer
  2. When to use specialized studies such as MRI
PET Imaging of Lung Cancer
  1. Role of FDG in diagnostic algorithm
  2. FDG pet in the prognostication of lung cancer
  3. FDG pet in the determination of response to therapy


Chemotherapy and Targeted Agents for Lung Cancer

Maintenance Therapy in NSCLC
  1. Concept of maintenance
  2. Old studies testing the concept
  3. Switch maintenance vs. continuation maintenance
  4. Review of recent randomized studies
  5. Meta-analyses
  6. Which drug and which patients?
Pharmacogenomics and Lung Cancer
  1. Review the concept of pharmacogenomics in lung cancer
  2. The DNA repair machinery and potential candidate genes
  3. Other potential candidate genes
  4. Gene microarray as a predictive tool of the efficacy of cancer chemotherapy
  5. Other predictive tools
New Targetable Pathways in Lung Cancer
  1. New targets in NSCLC more specifically in adenocarcinoma (ras- raf pathway, MEK inhibitors, potential for M-TOR inhibitors)
Management of Toxicities of Targeted Therapies
  1. Toxicities associated with targeted therapies in lung cancer
  2. Preventive measures and treatment
  3. Discussion of Ethnic variations
Immunotherapy and Lung Cancer
  1. Immunological dysfunction in lung cancer
  2. Review of the supportive evidence for immunotherapy in lung cancer
  3. Review of agents and clinical studies
Statistical Methodology
  1. Design and endpoint considerations for imaging based studies
  2. Early phase trial designs: patient selection, endpoints, design, and analyses


Other Thoracic Malignancies

Malignant Mesothelioma
  1. Biology of pleural mesothelioma
  2. Biomarkers
  3. Chemotherapy
  4. Surgery
  5. Multimodality
  6. New therapies